Explore Our Network

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

Ambient Biosciences is a global leader in biostabilization, dedicated to eliminating cold chain reliance and improving global health equity through innovative biomolecule stabilization technology. Their patented Capillary-Assisted Vitrification (CAV) process enables room-temperature storage and shipping of sensitive reagents and biomolecules, offering a superior alternative to traditional lyophilization and cryopreservation. With a values-driven, diverse team of scientific experts and visionary leaders, Ambient Biosciences is committed to transforming laboratory operations, reducing costs and waste, and making life sciences more accessible and sustainable worldwide.

Anavatos Bio is an early-stage biotechnology start-up based in Seattle, Washington, dedicated to revolutionizing biologics manufacturing. The company is driven by a team of experienced scientists, engineers, and entrepreneurs passionate about increasing access to protein therapeutics. Their mission is to enable faster, more efficient, and cost-effective production of biologics at smaller scales, supporting early-phase research and advancing a new medical paradigm that delivers greater value to patients.

AntoXa Corporation is a Canadian biopharmaceutical company that develops plant-based medical countermeasures aimed at protecting military and civilian populations from biological and chemical threats, as well as emerging infectious diseases. Leveraging a proprietary plant molecular farming platform, AntoXa focuses on producing safe, effective, and affordable therapeutics such as antidotes for bioterrorism agents and treatments for pandemic threats. The company specializes in rapid, scalable manufacturing of recombinant proteins and antibodies for use in national stockpiles and public health emergency preparedness.

Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.

ARIScience is at the forefront of drug discovery, leveraging a unique combination of AI, quantum chemistry, computer vision, and biochemistry to develop novel small molecule drugs. Their mission is to reduce the burden of human disease by discovering therapeutics that interrupt disease pathways. With a focus on neurodegenerative, inflammatory, and infectious diseases, ARIScience employs cutting-edge in silico methods to efficiently identify and optimize drug candidates. Their commitment to innovation and collaboration with leading institutions positions them to make a significant impact on human health. ARIScience is creating value in two ways: Value 1: ARIScience is developing small molecule assets targeting respiratory depression, cutaneous burn and radiation injuries, antivirals for EBOV and DENV, bacteriostatic antibiotic targeting Staph aureus. Value 2: It's novel AI driven quasi quantum chemistry (AI+QQ) small molecule discovery platform for precision protein inhibition and potentiation.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.

Athari BioSciences is a CLIA-certified BSL-2 diagnostic, research, and training laboratory advancing healthcare through scientific innovation in diagnostics, therapeutics, genomic research, and workforce development. With a mission focused on improving health equity, personalized medicine, and education, the company provides laboratory, research, and regulatory services, and offers hands-on learning experiences to foster the next generation of life sciences professionals.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

Bench in a Box Technologies develops point-of-care diagnostic platforms tailored for field and low-resource environments. The company's core technology, Protein Signal Amplification (PSA), allows rapid, electricity-free molecular detection at room temperature, delivering results in five minutes or less, without the need for refrigeration or specialized laboratory infrastructure. Drawing on extensive expertise in molecular diagnostics, drug development, and logistics, the company aims to make high-quality diagnostics broadly accessible.

BioBridge Global is a nonprofit organization dedicated to saving and enhancing lives through the healing power of human cells and tissue. It operates a family of nonprofits including South Texas Blood & Tissue, QualTex Laboratories, GenCure, and The Blood & Tissue Center Foundation. The organization provides lifesaving therapies to patients and supports advances in advanced therapies, focusing on blood, cell, and tissue products, testing services, and the development of new therapies.

BioFactura, Inc., based in Frederick, Maryland, is a biopharmaceutical company specializing in the development and commercialization of high-value biosimilars, biodefense medical countermeasures, and novel drugs. Leveraging its proprietary StableFast™ Biomanufacturing Platform, BioFactura delivers faster, lower-cost, and superior-quality biologics. With over a decade of experience, the company has advanced life-saving medicines from research to patient care, focusing on unmet global biomedical and national biodefense needs. Its portfolio includes drugs for smallpox, Ebola, cancer, autoimmune, and infectious diseases.

Bioneer is a biotechnology company specializing in molecular biology, offering solutions in nucleic acid synthesis, molecular diagnostics, protein production, and laboratory automation. The company's expertise covers oligonucleotide chemistry, gene synthesis, sample preparation, molecular diagnostics, and analytical services such as mass spectrometry and sequencing, serving clinical, research, and industrial sectors globally.

BioPharma Connections is an independent, woman-owned consulting firm founded in San Francisco in 2007, providing strategic business development, technical operations, regulatory, product development, and commercialization support to the life sciences industry. Serving pharmaceutical, biotechnology, medical device, and diagnostic companies globally, the firm specializes in facilitating connections between organizations, service providers, CROs, CDMOs, and investors—guiding clients from concept to commercialization, with deep expertise in regulatory compliance, emerging technologies, and diverse therapeutic areas.

Biophoundry specializes in advancing scalable engineered phage-based solutions for therapeutics, diagnostics, and bio-molecular engineering. It is shifting the paradigm from phage discovery to phage design. Its team leverages expertise in synthetic biology, machine learning, and data science to accelerate the development of precision antibiotics and address critical healthcare challenges such as antimicrobial resistance.

BiosYnth s.r.l. is a biotechnology firm specializing in the research, development, and innovation of bacterial and viral vaccine platforms. With over 40 years of expertise, the company focuses on glycoconjugate, nanostructured vector, and synthetic peptide technologies to address invasive infectious diseases and antibiotic resistance. Operations comply with GLP and GMP standards and are supported by a robust patent portfolio and international collaborations.

Blood Centers of America (BCA) is the largest blood supply network in the United States, comprising over 60 independent community blood centers that collectively distribute approximately 50% of the nation's blood supply. BCA supports member organizations through supply chain solutions, donor recruitment, advocacy, disaster response, and purchasing power. In addition to providing whole blood, red blood cells, platelets, plasma, cells, and tissues for therapeutic, diagnostic, research, and advanced therapy applications, BCA and its network are engaged in the development and delivery of advanced therapies including cell and gene therapy starting materials, processing, and manufacturing. BCA actively mobilizes resources in response to national emergencies, pandemics, and technological advances in donor experience and biotherapeutics.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.